EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EVALUATION OF THE ROLE OF FECAL CALPROTECTIN AS A BIOMARKER OF ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH CROHN’S DISEASE

Leith Abdul Hussein Abdullah, Hassan Mohammed Abbas, Halaa Ali Hussien

Global Journal of Public Health Medicine · 2026

DOI: 10.37557/33f44713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Journal of Public Health Medicine, 2026. Verfasst von Leith Abdul Hussein Abdullah und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Crohn's disease is a chronic inflammatory bowel illness with transmural inflammation and diverse clinical manifestations. Accurate assessment of disease activity is required to guide treatment and improve patient outcomes. This study assessed the diagnostic efficacy of fecal calprotectin as a biomarker of endoscopic disease activity in patients with Crohn's disease undergoing biologic therapy.

Methods

We conducted this prospective cohort study of 70 patients at Baghdad Teaching Hospital/Medical City between January 2024 and January 2025. We measured disease activity using the Simple Endoscopic Score for Crohn's Disease (SES-CD). We classified endoscopic activity as remission (0-2), mild activity (3-6), moderate activity (7-15), or severe activity (?16).

Results

Among the 70 patients, 51 (72.8%) were in remission, while 19 (27.2%) had active disease after treatment. Active patients had significantly higher post-treatment fecal calprotectin levels than those in remission (367.89 vs. 111.83 ?g/g, P < .001). ROC analysis showed an area under the curve of 0.835 (P < .001). A fecal calprotectin cutoff of ?148.5 ?g/g resulted in 89.4% sensitivity, 70.6% specificity, 53.1% positive predictive value, and 94.7% negative predictive value.

Conclusion

Fecal calprotectin effectively detects endoscopic disease activity in patients with Crohn's disease. Its high sensitivity and negative predictive value suggest it could be useful as a noninvasive monitoring tool, but the results should be interpreted in the context of this single-center investigation.

Zitieren

APA

Abdullah, L. A. H., Abbas, H. M., & Hussien, H. A. (2026). EVALUATION OF THE ROLE OF FECAL CALPROTECTIN AS A BIOMARKER OF ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH CROHN’S DISEASE. Global Journal of Public Health Medicine. https://doi.org/10.37557/33f44713

Vancouver

Abdullah LAH, Abbas HM, Hussien HA. EVALUATION OF THE ROLE OF FECAL CALPROTECTIN AS A BIOMARKER OF ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH CROHN’S DISEASE. Global Journal of Public Health Medicine. 2026. doi:10.37557/33f44713

BibTeX
@article{Abdullah2026,
  author = {Abdullah, Leith Abdul Hussein and Abbas, Hassan Mohammed and Hussien, Halaa Ali},
  title = {EVALUATION OF THE ROLE OF FECAL CALPROTECTIN AS A BIOMARKER OF ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH CROHN’S DISEASE},
  journal = {Global Journal of Public Health Medicine},
  year = {2026},
  doi = {10.37557/33f44713}
}
Kostenlos starten →